CAMBRIDGE, Mass., June 7 /PRNewswire-FirstCall/ -- ViaCell, Inc. (Nasdaq: VIAC - News) today announced that Jim Corbett, President of ViaCell Reproductive Health, will present an update on its product pipeline and business activities at the 2006 Pacific Growth Equities Life Sciences Growth Conference on Wednesday, June 14, 2006 at 1:30 p.m. Pacific Time at the InterContinental Mark Hopkins Hotel in San Francisco, California. A live audio webcast of the presentation will be available on the Investor Information section of the ViaCell website at http://www.viacellinc.com. A replay of the presentation will be available for approximately three months after the webcast.
ViaCell is a biotechnology company focused on enabling the widespread use of human cells as medicine. The Company is developing a pipeline of proprietary stem cell product candidates intended to address cancer, cardiac disease, and diabetes. CB001, its lead cord blood derived stem cell therapy product candidate, is being developed for hematopoietic stem cell transplantation in patients affected by a variety of cancers. In addition to its therapeutic development programs, ViaCell’s reproductive health business commercializes ViaCord®, a product that offers expecting families the option of preserving their baby’s umbilical cord blood. The Company is working to leverage its commercial infrastructure and product development capabilities by developing ViaCyte(SM), its investigational product intended to broaden reproductive choices for women through the cryopreservation of human unfertilized eggs. ViaCell is headquartered in Cambridge, Massachusetts with a processing and storage facility in Kentucky and additional research and development operations in Singapore. Additional information about ViaCell is available online at http://www.viacellinc.com.
ViaCell® and ViaCord® are registered trademarks and ViaCyte(SM) is a service mark of ViaCell, Inc.
For More Information Contact: Justine E. Koenigsberg Senior Director, Corporate Communications (617) 914-3494
Source: ViaCell, Inc.
